Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity

Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine kinase inhibitor cabozantinib showed striking responses in cancer clinical trial p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Discov
Hauptverfasser: Patnaik, Akash, Swanson, Kenneth D., Csizmadia, Eva, Solanki, Aniruddh, Landon-Brace, Natalie, Gehring, Marina P., Helenius, Katja, Olson, Brian M., Pyzer, Athalia R., Wang, Lily C., Elemento, Olivier, Novak, Jesse, Thornley, Thomas B., Asara, John M., Montaser, Laleh, Timmons, Joshua J., Morgan, Todd M., Wang, Yugang, Levantini, Elena, Clohessy, John G., Kelly, Kathleen, Pandolfi, Pier Paolo, Rosenblatt, Jacalyn M., Avigan, David E., Ye, Huihui, Karp, Jeffrey M., Signoretti, Sabina, Balk, Steven P., Cantley, Lewis C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501767/
https://ncbi.nlm.nih.gov/pubmed/28274958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0778
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge